G. Simon

发表

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

C. Slapak, D. Spriggs, E. Haura, 2011, Cancer Chemotherapy and Pharmacology.

Small cell lung cancer

G. Kalemkerian, G. Simon, H. Wagner, 2010, Seminars in Respiratory and Critical Care Medicine.

A Novel Classification of Lung Cancer into Molecular Subtypes

Jeff Shrager, R. Bueno, R. Salgia, 2012, PloS one.

Multiplexed specific label-free detection of NCI-H358 lung cancer cell line lysates with silicon based photonic crystal microcavity biosensors.

Ray T. Chen, Swapnajit Chakravarty, Yi Zou, 2013, Biosensors & bioelectronics.

Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer.

Joe Y. Chang, P. Thall, D. Gomez, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Non-small cell lung cancer.

D. Ettinger, M. Kris, G. Bepler, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.

M. Fishman, J. Lee, A. Daud, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a Phase II Trial of Gemcitabine Plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-Ceramide as a Novel Biomarker for Monitoring Response

Y. Hannun, M. B. Gillespie, C. Senkal, 2011, Clinical Cancer Research.

You just can't call it lung cancer anymore.

G. Silvestri, G. Simon, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Docetaxel plus cisplatin in non-small-cell lung cancer

V. Georgoulias, S. Ramalingam, G. Simon, 2004 .

Biology of Human Tumors VEGF / VEGFR-2 Upregulates EZH 2 Expression in Lung Adenocarcinoma Cells and EZH 2 Depletion Enhances the Response to Platinum-Based and VEGFR-2 – Targeted Therapy

Milind B. Suraokar, K. Coombes, Jing Wang, 2014 .

VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2–Targeted Therapy

K. Coombes, Jing Wang, J. Minna, 2014, Clinical Cancer Research.

Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

A. Turrisi, G. Simon, N. Aronson, 2007, Chest.

ACCP Evidence-Based Clinical Practice : * Management of Small Cell Lung Cancer

A. Turrisi, G. Simon, 2007 .

Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

A. Turrisi, G. Simon, George R Simon, 2007, Chest.

A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin

Suzanne F. Jones, H. Burris, J. Infante, 2015, Investigational New Drugs.

A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.

I. Macpherson, R. Gedrich, G. Simon, 2013, European journal of cancer.

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker

P. Munster, D. Sullivan, A. Daud, 2009, British Journal of Cancer.

Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer.

G. Bepler, G. Simon, M. Begum, 2008, Future oncology.

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies

K. Hess, J. Heymach, F. Meric-Bernstam, 2020, ESMO Open.

Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer.

C. Obasaju, G. Simon, C. Manegold, 2013, Clinical lung cancer.

Small-cell lung cancer.

R. Ginsberg, G. Simon, J. Ruckdeschel, 2001, Chest surgery clinics of North America.

Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer.

Joe Y. Chang, K. Hess, J. Welsh, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study

G. Bepler, M. Fishman, P. Munster, 2006, Clinical Cancer Research.

Pharmacogenomic applications in the management of Non-Small Cell Lung Cancer (NSCLC): from clinical trials to clinical practice: Y1-17

G. Simon, 2007 .

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial

Joe Y. Chang, K. Hess, J. Welsh, 2020, Journal for ImmunoTherapy of Cancer.

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

G. Bepler, A. Cantor, G. Simon, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution.

G. Bepler, A. Cantor, E. Haura, 2003, Cancer control : journal of the Moffitt Cancer Center.

Gefitinib ( ZD 1839 ) in Previously Treated Advanced Non – Small-Cell Lung Cancer : Experience From a Single Institution

G. Bepler, A. Cantor, E. Haura, 2003 .

Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.

J. Roth, I. Wistuba, J. Lee, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Malignant pleural mesothelioma: a comprehensive review.

G. Bepler, C. Garrett, G. Simon, 2006, Cancer control : journal of the Moffitt Cancer Center.

A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer.

N. Simon, G. Simon, N. Somaiah, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study

C. Cleeland, T. Mendoza, K. Kehl, 2019, Supportive Care in Cancer.

Phase I Study of theTaxane BMS-188797 in Combinationwith Carboplatin Administered Every 3 Weeks in Patients with SolidMalignancies

M. Fishman, A. Cantor, D. Sullivan, 2006 .

Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies

M. Fishman, A. Cantor, D. Sullivan, 2006, Clinical Cancer Research.

Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses

Joe Y. Chang, K. Hess, D. Gomez, 2019, Cancer Immunology Research.

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.

Joe Y. Chang, J. Welsh, Steven H. Lin, 2020, The Lancet. Respiratory medicine.

P2.04-09 Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

S. Swisher, J. Heymach, A. Reuben, 2018, Journal of Thoracic Oncology.

Molecular targeted agents and biologic therapies for non-small cell lung cancer.

G. Simon, N. Somaiah, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM).

L. Bloss, C. Obasaju, K. Kelly, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Silicon photonic crystal microcavity biosensors for label free highly sensitive and specific lung cancer detection

W. Lai, S. Chakravarty, R. Gemmill, 2012, IEEE Photonics Conference 2012.

Taxanes in the Treatment of Advanced (Stage III and IV) Non-small Cell Lung Cancer (NSCLC): Recent Developments

P. Bunn, G. Simon, 2003, Cancer investigation.

A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC

S. Piha-Paul, A. Dowlati, G. Simon, 2022, JTO clinical and research reports.

SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping

J. Riess, T. Shaffer, P. Martínez, 2021, JTO clinical and research reports.

Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study.

M. Suarez‐Almazor, A. Lok, S. Cantor, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of CT-2106 (polyglutamated camptothecin) administered weekly in patients (pts) with advanced solid tumors.

P. Munster, A. Daud, C. Garrett, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors

Daniel Sullivan, E. Haura, G. Simon, 2007, Cancer.

Impact of the timing of hepatitis B virus identification and anti–hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy

M. Suarez‐Almazor, A. Lok, S. Cantor, 2017, Cancer.

Randomized phase I/II trial of pembrolizumab with and without radiotherapy for metastatic non-small cell lung cancer.

Joe Y. Chang, K. Hess, J. Welsh, 2019, Journal of Clinical Oncology.

Depletion of CD34+ CD4+ cells in bone marrow from HIV-1-infected individuals.

E. Shpall, G. Harrison, G. Simon, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines.

S. Chellappan, S. Rastogi, Sarmistha Banerjee, 2007, Cancer letters.

ALK: a tyrosine kinase target for cancer therapy

Md Abu Shufean, Amber M. Johnson, Nora S. Sanchez, 2017, Cold Spring Harbor molecular case studies.

Molecular pathways and therapeutic targets in lung cancer

Ravi Salgia, Raphael Bueno, R. Bueno, 2014, Oncotarget.

Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.

S. Swisher, A. Reuben, Jianhua Zhang, 2018 .

Recent Advances in Immunotherapy in Metastatic NSCLC

Y. Boumber, G. Simon, P. Bansal, 2016, Front. Oncol..

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab

C. Garrett, G. Simon, D. Hoda, 2008, Therapeutics and clinical risk management.

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

C. Rudin, P. Hammerman, R. Govindan, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.

J. Minna, I. Wistuba, J. Lee, 2016, Cancer research.

nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive update.

G. Simon, 2014, Clinical lung cancer.

Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations

Hannah C. Beird, F. Meric-Bernstam, P. Hwu, 2018, Oncotarget.

ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer.

G. Bepler, A. Cantor, G. Simon, 2005, Chest.

Phase II Study of First-Line Sequential Chemotherapy with Gemcitabine-Carboplatin Followed by Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer

G. Bepler, E. Haura, G. Simon, 2005, Oncology.

NCCN Non – Small Cell Lung Cancer Clinical Practice Guidelines in Oncology

D. Ettinger, M. Kris, G. Bepler, 2010 .

Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis.

G. Simon, A. Frederickson, M. Lorenzi, 2019, Immunotherapy.

Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.

K. Hess, F. Meric-Bernstam, F. Janku, 2018, Lung cancer.

Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC

Y. Boumber, G. Simon, P. Bansal, 2016, Front. Oncol..

The role of molecular analyses in the era of personalized therapy for advanced NSCLC.

N. Pastis, N. Tanner, G. Silvestri, 2012, Lung cancer.

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

Eric B Haura, Bhupendra Rawal, Michael J Schell, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer.

Alan Cantor, George Simon, G. Bepler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer

G. Bepler, E. Haura, Dung-Tsa Chen, 2018, Cancer Immunology, Immunotherapy.

Systemic therapy for lung cancer

K. Shirai, G. Simon, C. Sherman, 2013 .

Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality.

G. Bepler, G. Simon, R. Ismail-Khan, 2007, The international journal of biochemistry & cell biology.

Antiangiogenic agents in the management of non-small cell lung cancer

G. Simon, C. Aggarwal, N. Somaiah, 2012, Cancer biology & therapy.

Summary of Presentations from the Ninth Annual Targeted Therapies in Lung Cancer Symposium

R. Govindan, G. Simon, N. Somaiah, 2009 .

Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung.

G. Bepler, A. Cantor, G. Simon, 2004, Chest.

Lung adenocarcinoma with Concurrent KRAS Mutation and ALK Rearrangement Responding to Crizotinib: Case Report

M. Routbort, G. Simon, Xinyan Lu, 2015, The International journal of biological markers.

Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?

G. Simon, C. Aggarwal, N. Somaiah, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

G. Bepler, M. Schell, S. Gadgeel, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.

C. Obasaju, P. Jänne, P. Fidias, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 trial of docetaxel and gefitinib in the first‐line treatment of patients with advanced nonsmall‐cell lung cancer (NSCLC) who are 70 years of age or older

Eric B Haura, Michael J Schell, Rachna Kapoor, 2008, Cancer.

Recent advances in lung cancer: summary of presentations from the 45th annual meeting of the American Society of Clinical Oncology (2009).

R. Govindan, A. Wozniak, T. Stinchcombe, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Long‐term safety and survival with gefitinib in select patients with advanced non–small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP)

L. Sequist, F. Hirsch, P. Bunn, 2018, Cancer.

Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial

M. Fishman, A. Cantor, P. Munster, 2006, Molecular Cancer Therapeutics.

Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

Alan Cantor, Frank Walsh, George Simon, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

M. Fishman, T. Holzer, F. Meric-Bernstam, 2011, Clinical Cancer Research.

Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung

T. Hensing, K. Shirai, G. Simon, 2014, Oncoscience.

Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer

Shouhao Zhou, S. Giordano, K. Kehl, 2017, Clinical lung cancer.

Non‐Small Cell Lung Cancers (NSCLC) with Mutations in BRAF

G. Simon, R. Ferrarotto, 2014 .

Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer.

H. Borghaei, R. Mehra, G. Simon, 2009, Future oncology.

Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer

C. Obasaju, G. Bepler, A. Cantor, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)

A. Tsao, D. Gibbons, J. Kurie, 2018, Journal of Thoracic Oncology.

Phase II Trial of a GM-CSF-producing and CD40L-expressing Bystander Cell Line Combined With an Allogeneic Tumor Cell–based Vaccine for Refractory Lung Adenocarcinoma

G. Bepler, M. Schell, E. Haura, 2013, Journal of immunotherapy.

Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer

G. Bepler, T. Garrett, G. Simon, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Award Number: W81XWH-07-1-0348 TITLE: Development of Anti-GLUT-1 Antibody as a Novel Therapeutic Strategy against Breast Cancer

Sarmistha Banerjee, G. Simon, D. M., 2008 .

Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

G. Bepler, W. Janssen, S. Chada, 2006, Clinical Cancer Research.

Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC

Joe Y. Chang, P. Thall, Steven H. Lin, 2020 .

Individualizing Chemotherapy for Non-small Cell Lung Cancer (NSCLC) in the Adjuvant and Advanced Setting: Current Status and Future Directions

G. Simon, 2008, Current treatment options in oncology.

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

J. Hainsworth, K. Pierce, C. Langer, 2007, Cancer Chemotherapy and Pharmacology.

Phase I pharmacokinetic (PK) and safety study of intravenous (IV) CI-1033 in patients with advanced solid tumors.

D. Sullivan, C. Garrett, G. Simon, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non–Small Cell Lung Cancer

I. Wistuba, J. Lee, S. Swisher, 2020, Clinical Cancer Research.

A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

I. Wistuba, J. Lee, A. Tsao, 2020, The oncologist.

Phase I/II Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage Small Cell Lung Cancer.

Joe Y. Chang, K. Hess, J. Welsh, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer.

G. Bepler, T. Garrett, G. Simon, 2011, Oncoimmunology.

Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.

C. Obasaju, P. Jänne, K. Kelly, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies

J. Homsi, P. Munster, D. Sullivan, 2007, Clinical Cancer Research.

Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care.

Daniel Gomez, Lynda Chin, Koichi Takahashi, 2018, The oncologist.

A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer.

G. Simon, N. Somaiah, George R Simon, 2014, Clinical lung cancer.

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

Suzanne F. Jones, F. Gao, R. Govindan, 2007, Clinical Cancer Research.

What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer.

C. Cleeland, T. Mendoza, Jianjun Zhang, 2020, JCO Oncology Practice.

EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma

I. Wistuba, J. Lee, S. Swisher, 2013, Clinical Cancer Research.

Molecular predictors of chemotherapy response in non-small-cell lung cancer

G. Bepler, G. Simon, J. Gray, 2007, Expert review of anticancer therapy.

Molecular analysis-based treatment strategies for non-small cell lung cancer.

G. Bepler, G. Simon, M. Begum, 2008, Cancer control : journal of the Moffitt Cancer Center.

Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non‐small cell lung cancer

I. Wistuba, C. Behrens, J. Rodriguez-Canales, 2019, Cancer medicine.

Preliminary indication of survival benefit from ERCC1 and RRM1‐tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis

G. Bepler, M. Schell, E. Haura, 2012, Cancer.

Adjuvant chemotherapy for non-small cell lung cancer

G. Simon, E. Crane, 2006, Current treatment options in oncology.

Imaging , Diagnosis , Prognosis EZH 2 Protein Expression Associates with the Early Pathogenesis , Tumor Progression , and Prognosis of Non – Small Cell Lung Carcinoma

I. Wistuba, J. Lee, S. Swisher, 2013 .

Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgery.

H. Borghaei, R. Mehra, C. Langer, 2014, Cancer control : journal of the Moffitt Cancer Center.

Physician Preferences for Management of Patients with Stage IIIA NSCLC: Impact of Bulk of Nodal Disease on Therapy Selection

N. Tanner, G. Silvestri, Mark R. Green, 2012, Journal of Thoracic Oncology.

Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer

G. Bepler, D. Boulware, D. Sullivan, 2008, Clinical Cancer Research.

Phase II Trial of Induction Gemcitabine and Carboplatin Followed by Conformal Thoracic Radiation to 74 Gy with Weekly Paclitaxel and Carboplatin in Unresectable Stage III Non-small Cell Lung Cancer

G. Bepler, C. Stevens, T. Dilling, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).

P. A. Futreal, J. Roth, I. Wistuba, 2019, Journal of Clinical Oncology.

Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: focus on non-small cell lung cancer (2010).

R. Govindan, T. Stinchcombe, G. Simon, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations

J. Lee, Jianjun Zhang, X. Le, 2021, JTO clinical and research reports.

Docetaxel and gefitinib in the first-line treatment of elderly patients (≥70) with advanced non-small cell lung cancer (ANSCLC): Results of phase II trial

G. Bepler, E. Haura, T. Galloway, 2005 .

Targeting I2PP2A by FTY720: A novel, mechanism-based treatment strategy for patients with advanced and previously treated non-small cell lung cancer (NSCLC).

Y. Hannun, Y. Peterson, D. Perrotti, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abscopal Response Rates after Salvage Radiation in Patients with Progressive Disease on Immunotherapy

J. Welsh, D. Hong, Chad Tang, 2020 .

O-259 PTEN, RRM1, and ERCC1 are coexpressed in non-small-cell lung cancer (NSCLC) and are predictive of survival

G. Bepler, A. Cantor, G. Simon, 2003 .

MA09.03 Identification of Mechanisms of Acquired Resistance to Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)

A. Tsao, Limei Hu, D. Gibbons, 2019, Journal of Thoracic Oncology.

Treatment of older patients with non-small-cell lung cancer: walking the therapeutic tightrope.

G. Simon, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.

K. Hess, D. Carbone, R. Salgia, 2018 .

Molecular targeted agents and biologic therapies for lung cancer.

G. Simon, N. Somaiah, George R Simon, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Antiangiogenic agents in the management of non-small cell lung cancer

G. Simon, C. Aggarwal, N. Somaiah, 2012, Cancer biology & therapy.

Treatment of older patients with non-small-cell lung cancer: walking the therapeutic tightrope.

G. Simon, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular analysis-directed, international, phase III trial in patients with advanced non-small-cell lung cancer.

G. Bepler, M. Schell, S. Gadgeel, 2013 .

Molecular analysis-directed individualized therapy (MADeIT) in advanced non-small cell lung cancer (NSCLC)

G. Bepler, E. Haura, G. Simon, 2007 .

VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2–Targeted Therapy

Milind B. Suraokar, K. Coombes, Jing Wang, 2014, Clinical Cancer Research.

Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC).

J. Hainsworth, C. Langer, R. Cohen, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

4 Bone Sarcoma ... Turning the Corner

Shawna V. Hudson, V. Sondak, G. Bepler, 2008 .

Abstract 4997: Responsiveness to immune checkpoint inhibitors in RET dependent cancers

K. Hess, F. Meric-Bernstam, D. Hong, 2019, Immunology.

Phase II Trial of a GM-CSF-producing and CD40L-expressing Bystander Cell Line Combined With an Allogeneic Tumor Cell–based Vaccine for Refractory Lung Adenocarcinoma

G. Bepler, M. Schell, E. Haura, 2013, Journal of immunotherapy.

Physician Preferences for Management of Patients with Stage IIIA NSCLC: Impact of Bulk of Nodal Disease on Therapy Selection

N. Tanner, G. Silvestri, Mark R. Green, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.